Pfizer
PFE · NYSE · Pharma · United States
$25.21
-3.2%
as of Jun 18, 2026, 8:03 PM
52-week range
$23.11 – $28.75
P/E (TTM)
11.9
ROE
9.0%
Volume
67,907,094
New to these? P/E, ROE, ROCE and more in Learn.
Ask MarketChacha about PFE
Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.
Financials
Revenue trend
Yearly
| Period | Revenue | Net profit | EPS | Net margin | ROE |
|---|---|---|---|---|---|
| FY2025 | — | $7.8B | 1.36 | — | 9.0% |
| FY2024 | — | $8.0B | 1.41 | — | 9.1% |
| FY2023 | $50.9B | $2.1B | 0.37 | 4.2% | 2.4% |
Quarterly
| Period | Revenue | Net profit | EPS | Net margin | ROE |
|---|---|---|---|---|---|
| 2026Q1 | — | $2.7B | 0.47 | — | — |
| 2025Q3 | — | $3.5B | 0.62 | — | — |
| 2025Q2 | — | $2.9B | 0.51 | — | — |
| 2025Q1 | — | $3.0B | 0.52 | — | — |
| 2024Q3 | — | $4.5B | 0.78 | — | — |
| 2024Q2 | — | $41.0M | 0.01 | — | — |
| 2024Q1 | — | $3.1B | 0.55 | — | — |
| 2023Q4 | — | $-2.4B | -0.42 | — | — |
| 2023Q3 | — | $2.3B | 0.41 | — | — |
| 2023Q2 | — | $5.5B | 0.97 | — | — |
Figures as reported, in reporting currency. Source: SEC XBRL.
Filings & announcements
2026
- SEC6/18/2026material
- SEC6/18/2026material
- SEC5/5/2026material
- SEC5/5/2026
- SEC4/27/2026material
- SEC2/26/2026
In the news
- Stock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 Outlook - The Motley Fool· The Motley Fool
- Stock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 Outlook - Yahoo Finance· Yahoo Finance
- Pfizer Stock Drops Today As CFO Steps Down In August - Benzinga· Benzinga
- Pfizer Stock Falls as CFO Dave Denton Exit Revives Questions on Growth Plan - TechStock²· TechStock²
- Can Pfizer Take Share From Lilly & Novo Nordisk in the Obesity Space? - TradingView· TradingView
- Pfizer Stock And Two AI Healthcare Plays That Look Mispriced - simplywall.st· simplywall.st
- Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax? - 24/7 Wall St.· 24/7 Wall St.
- Here's When Pfizer's CEO Says the Company Might Get Back to Generating High-Single-Digit Growth - The Motley Fool· The Motley Fool
- Is Pfizer's Discounted Valuation a Buying Opportunity or a Value Trap? - The Globe and Mail· The Globe and Mail
- Pfizer (PFE) Stock Valuation Check As Modest Recent Gains Meet Mixed Multi Year Returns - simplywall.st· simplywall.st
Education and discussion only — not investment advice. Data from official filings (SEC/BSE), Yahoo Finance, and Google News. Verify with the linked sources before acting.